THE LINK BETWEEN PSORIASIS AND THE IMMUNOLOGICAL PATHOGENESIS OF ATHEROSCLEROSIS
Keywords:
Psoriasis, Atherosclerosis, Immunology, PathogenesisAbstract
Psoriasis and atherosclerosis are both chronic inflammatory diseases, morphologically manifested as "plaques", but the affected target organs are different. Pro Clinical epidemiological studies suggest that there is a correlation between psoriasis and atherosclerosis. Now, from the perspective of their immunological mechanisms and inflammatory pathways, we will analyze their immunological Do a literature review on the relationship between pathogenesis.References
[1] Parisi R, Symmons DP, Griffiths CE, et al. Global epide- miology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol, 2013, 133 (2): 377-385.
[2] Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol, 2014, 32: 227-255.
[3] Monteleone G, Pallone F, MacDonald TT, et al. Psoriasis:from pathogenesis to novel therapeutic approaches. ClinSci(Lond), 2011, 120(1): 1-11.
[4] Reich K. The concept of psoriasis as a systemic inflamma- tion: implications for disease management. J Eur Acad Dermatol Venereol, 2012, 26(Suppl 2): 3-11.
[5] Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol, 2011, 12(3): 204-212.
[6] Libby P. History of discovery: inflammation of atherosclerosis. Arterioscler Thromb Vasc Biol, 2012, 32(9): 2 045-051.
[7] Gelfand JM, Neimann AL, Shin DB, et al. Riskof myocar- dial infarction in patients with psoriasis. JAMA, 2006, 296(14): 1 735-741.
[8] Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol, 2009, 23(11): 1 311-315.
[9] Kimball AB, Guerin A, Latremouille-Viau D, et al. Coro- nary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med, 2010, 123 (4): 350-357.
[10] Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med, 2011, 270(2): 147-157.
[11] Samarasekera EJ, Neilson JM, Warren RB, et al. Inci- dence of cardiovascular disease in individuals with psoria- sis: a systematic review and meta-analysis. J Invest Dermatol, 2013, 133(10): 2 340-346.
[12] Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol, 2012, 167(6): 1 345-350.
[13] Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol, 2009, 145(6): 700-703.
[14] Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol, 2009, 129(10): 2 411-418.
[15] Kaye JA, Li L, Jick SS. Incidence of risk factors for myo- cardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol, 2008, 159 (4): 895-902.
[16] Shaharyar S, Warraich H, McEvoy JW, et al. Subclinical cardiovascular disease in plaque psoriasis: association or causal link. Atherosclerosis, 2014, 232(1): 72-78.
[17] Gupta Y, Moller S, Zillikens D, et al. Genetic control of psoriasis is relatively distinct from that of metabolic syn- drome and coronary artery disease. Exp Dermatol, 2013, 22(8): 552-553.
[18] Lu YC, Chen HY, Nikamo Pin, et al.Association self cardiovascular and metabolic disease gene is with psoriasis 1 J 1 J Invest Dermatol, 2013, 133: 836-839.
[19] Koch M, Baurecht H, RiedJS, et al. Psoriasis and cardi- ometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol, 2015, 135 (5): 1283-293.
[20] Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol, 2008, 20: 401-407.
[21] Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007, 449: 564-569.
[22] Ganguly D, Chamilos G, Lande R, et al. Self-RNA-anti- microbial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med, 2009, 206: 1983-994.
[23] Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature, 2007, 445 (7130):866-873.
[24] Skalen K, Gustafsson M, Rydberg EK, et al. Subendothe- lial retention of atherogenic lipoproteins in early athero- sclerosis. Nature, 2002, 417: 750-754.
[25] Tabas I, Williams KJ, BorenJ. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation, 2007, 116: 1 832-844.
[26] Yan ZQ, Hansson GK. Innate immunity, macrophage acti- vation, and atherosclerosis. Immunol Rev, 2007, 219: 187-203.
[27] Ketelhuth DF, Hansson GK. Modulation of autoimmunity and atherosclerosis-common targets and promising transla- tional approaches against disease. Circ J, 2015, 79 (5): 924-933.
[28] Ghazizadeh R, Shimizu H, Tosa M, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci, 2010, 7(5): 284-289.
[29] Buckner JH. Mechanisms of impaired regulation by CD4+ CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol, 2010, 10: 849-859.
[30] Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and targettissue CD4+ CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained patho- geniceffector T cell proliferation. J Immunol, 2005, 174: 164-173.
[31] Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation&n